© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Aerie Pharmaceuticals announced Tuesday positive topline results for the phase 3 trial evaluating netarsudil 0.02% versus ripasudil 0.4% for the treatment of open-angle glaucoma and elevated IOP.
Aerie Pharmaceuticals announced Tuesday positive topline results for the Japan-based, phase 3 trial evaluating netarsudil ophthalmic solution 0.02% (netarsudil 0.02%) versus ripasudil hydrochloride hydrate ophthalmic solution 0.4% (ripasudil 0.4%).
As Rho kinase (ROCK) inhibitors, netarsudil 0.02% — known as Rhopressa® in the U.S. — and ripasudil 0.4% — known as Rhokiinsa® in the EU — are intended to treat open-angle glaucoma (OAG) and elevated intraocular pressure (IOP), according to a company news release.
The clinical trial included a single-masked comparison of netarsudil 0.02% dosed once daily versus ripasudil 0.4% dosed twice daily in 245 participants for four weeks.
Of the 245 patients, 122 received netarsudil 0.02% while 123 received ripasudil 0.4%. In total, 238 participants completed the study.
Trial results revealed that netarsudil 0.02% once daily was superior to ripasudil 0.4% daily in lowering at week 4 (p<0.0001), the primary endpoint for the study, the company reported.
The baseline mean diurnal IOP was 20.5 and 20.8 mmHg in the netarsudil 0.02% and ripasudil 0.4% arm, respectively.
Additionally, the mean diurnal IOP was significantly lower (16.0 mmHg) in the netarsudil 0.02% group compared to the ripasudil 0.4% group (17.7 mmHg, p<0.0001), the company stated.
At four weeks, netarsudil 0.02% reduced mean diurnal IOP by 4.7 mmHg (22.6%) from baseline compared to 3.0 mmHg (14.3%) with ripasudil 0.4% (p<0.0001), according to the company.
Aerie reported that both medications were well-tolerated, with the most common treatment emergent adverse event being conjunctival hyperemia (54.9% of subjects with netarsudil 0.02%; 62.6% of subjects with ripasudil 0.4%).
The trial was conducted in alignment with Japan’s Medical Devices Agency (PMDA) in anticipation of a potential regulatory submission of netarsudil 0.02% in Japan.
We believe that the statistically superior IOP-lowering of netarsudil versus the comparator in our study may suggest a very bright future for our product in Japan, a market where the comparator product is the only rho-kinase inhibitor commercially available,” said Benjamin F. McGraw, III, PharmD, Aerie’s interim executive chairman. “The IOP-lowering with netarsudil was consistent with that seen in the previous Phase 2 study conducted in Japan as well as in our ROCKET and MERCURY studies conducted in the United States for Rhopressa® and Rocklatan®, respectively.”
Safety data for at-home subcutaneous injection option for treatment of wet AMD, DME
Virtual reality gives ophthalmology students chance to view pupil abnormalities
Understanding the biological causes and cell types that lead to one of the leading causes of irreversible blindness worldwide could benefit treatment in patients